Biotrial collaborates on Study with Idorsia Pharmaceuticals Ltd.
Biotrial was pleased to collaborate on a recent study led by Pierre-Eric Juif, Markus S. Mueller, and Jasper Dingemanse at Idorsia Pharmaceuticals Ltd. The project focused on the lack of effect of Cenerimod, a selective S1P1 receptor modulator in development for the treatment of Systemic Lupus Erythematosus, on the pharmacokinetics of a combined oral contraceptive (COC).
Systemic Lupus Erythematosus is a disease that mainly affects women of childbearing potential, making the safety and efficacy of contraceptive methods during treatment of utmost importance. The study aimed to determine whether Cenerimod therapy posed a risk of interaction with COC as a method of contraception during and after treatment.
The study, which was supported by Biotrial, found that COC can be safely selected as a method of contraception during and after Cenerimod therapy, without any significant risk of interaction. The results of the study were recently published in the International Journal of Molecular Sciences – MDPI, and represent an important contribution to the field of Systemic Lupus Erythematosus treatment.
Biotrial is proud to have been a part of this study and to have contributed to the research into the safety and efficacy of Cenerimod therapy for patients with Systemic Lupus Erythematosus. Our team of experts has a wealth of experience in the conduct and management of clinical trials, and we are committed to supporting our clients in the development of safe and effective therapies for a range of diseases and conditions.
At Biotrial, we understand the importance of collaboration and knowledge-sharing in advancing medical research, and we are dedicated to contributing to the development of new treatments and therapies that can improve the lives of patients around the world.
